- Conditions
- Leukemia
- Interventions
- recombinant interferon alfa, cytarabine, imatinib mesylate
- Biological · Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 3,412
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myeloproliferative Neoplasms
- Interventions
- INCA035784
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Palo Alto, California • Denver, Colorado + 9 more
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, fludarabine phosphate, thiotepa, peripheral blood stem cell transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 5 more
- Conditions
- Germline Mutation, Myelodysplastic Syndromes, Acute Myeloid Leukemia
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Month to 120 Years
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Malignant Neoplasm, Metastatic Malignant Neoplasm to the Bone
- Interventions
- virtual non-calcium dual-energy computed tomography, computed tomography
- Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
- Interventions
- filgrastim, docetaxel
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 33
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 26 more
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- carboplatin, dasatinib, etoposide phosphate, ifosfamide, microarray analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, therapeutic conventional surgery, radiation therapy
- Drug · Genetic · Other + 2 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2022
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Leukemia
- Interventions
- filgrastim, busulfan, cytarabine, etoposide, methotrexate, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 15 Years to 69 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2009
- U.S. locations
- 3
- States / cities
- San Francisco, California • Baltimore, Maryland • Paterson, New Jersey
- Conditions
- Primary Myelofibrosis, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis
- Interventions
- RO7490677, Ruxolitinib
- Biological · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 7 more
- Conditions
- Leukemia,Myeloid, Chronic, Leukemia,Myeloid,Philadelphia-Positive
- Interventions
- Heat Shock Protein 70 HSP70
- Biological
- Lead sponsor
- University of Connecticut
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- filgrastim, graft-versus-tumor induction therapy, rituximab, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, cytarabine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, prednisone, vincristine sulfate, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Osteosarcoma, Bone Metastases
- Interventions
- 153Sm-DOTMP, External beam radiotherapy., Calcium Carbonate, Mozobil, Neupogen Injectable Product
- Drug · Radiation
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 15 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Leukemia, Lymphoma
- Interventions
- cyclophosphamide, allogeneic bone marrow transplantation, low-LET cobalt-60 gamma ray therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1990 – 2003
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Financial Stress, Hematologic Cancer, Survivorship
- Interventions
- CC Links
- Other
- Lead sponsor
- Jean Edward
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Hematologic Neoplasms
- Interventions
- Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine, Sirolimus, Filgrastim, Cyclophosphamide, Mesna, Total Body Irradiation (TBI)
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 85 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Philadelphia, Pennsylvania
- Conditions
- Cancer, Carcinoma, Castrate-Resistant Prostate Cancer, Prostate Cancer, Tumors
- Interventions
- Denosumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 27
- States / cities
- Huntsville, Alabama • Anaheim, California • Laguna Hills, California + 23 more
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- Diet
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific, Neutropenia
- Interventions
- BMS-247550, filgrastim
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome
- Interventions
- Decitabine, Gemtuzumab Ozogamicin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed Marginal B-cell Lymphoma, Relapsed Follicular Lymphoma, Lymphoplasmacytic Lymphoma
- Interventions
- Fludarabine, Melphalan, Total Body Irradiation
- Drug · Radiation
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Chronic Myelogenous Leukemia
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Anaheim, California • Los Angeles, California + 18 more
- Conditions
- Lymphoma, Multiple Myeloma, Leukemia, Myelodysplastic Syndrome
- Interventions
- Busulfan, Fludarabine, Cytoxan
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Houston, Texas • Seattle, Washington
- Conditions
- Solid Tumor Malignancy
- Interventions
- Pemigatinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 44
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more